ImmunoScape Announces Three Presentations Highlighting TCR Pipeline and Discovery Platform at the American Association for Cancer Research (AACR) Annual Meeting 2024
20 Mar 2024
ImmunotherapyAACRClinical StudyCell Therapy
SAN DIEGO & SINGAPORE--(BUSINESS WIRE)-- ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that three abstracts have been accepted for poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, California.
Presentation details are as follows:
Title: Discovery and development of T cell receptors targeting MAGE family antigens for adoptive T cell therapy against solid tumors
Presenter: Juliana Velez Lujan, Ph.D., ImmunoScape, Senior Scientist
Session Title: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T
Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 1
Poster Number: 13
Title: Deep Immunomics pipeline for discovery and validation of novel cancer-specific T cell receptors
Presenter: Hannah Fields, ImmunoScape, Scientist
Session Title: Adoptive Cell Therapies 1: Tumor Antigen Specific T-cells and TCR-T
Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 1
Poster Number: 8
Title: A validated bioinformatics tool-set for predicting TCR specificity
Presenter: Andreas Wilm, ImmunoScape, Director of Computational Biology
Session Title: Database Resources, Statistical Methods, and Other Tools
Date & Time: Monday, April 8, 2024, 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 36
Poster Number: 19
Full abstracts will be available on the AACR Online Program Planner. Following the conference, the posters will be made available under the “Publications” page on ImmunoScape's website.
About ImmunoScape
ImmunoScape is a biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.